Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.546NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.194NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.429.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.1.9 (Gamma)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.25.1.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.203NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.157NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.176NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.3.4 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.391NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.393NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.432NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.388NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.6NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.48NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.112NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.274NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.515NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.258.23NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.370NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.118NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.309NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.632NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.72NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.108NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.332NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.109NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.361NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.38NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.12NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.417NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AM.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.258.20NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.36.37NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.319NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.182NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.430NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.331NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.112.3 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.37NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
N.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.431NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.12NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.170NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.23NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.506NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.6.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.438.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used